Podcast

Speaking of Urology podcast: Dr. Angela Smith discusses Jelmyto for low-grade UTUC

Author(s):

Urology Times staff

In this episode, Angela B. Smith, MD, MS, of UNC Lineberger Comprehensive Cancer Center, discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.

Related Videos
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
How recombinant BCG could ease strain of supply issues
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
John Taylor, III, MD, on novel options in NMIBC
John Taylor, III, MD, on novel options in NMIBC
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
What a long-term study of patients undergoing RARC reveals about upstaging
Sima Porten, MD, on the increased risk of bladder cancer among firefighters
Sima Porten, MD, on the increased risk of bladder cancer among firefighters
Jason Hafron, MD, predicts coming advancements in bladder cancer
Jason Hafron, MD, predicts coming advancements in bladder cancer
Related Content
Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
April 2nd 2025

The importance of federal funding in cancer research: A call to action

Michael S. Cookson, MD, MMHC
"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Subcutaneous nivolumab under review in EU for solid tumors
March 31st 2025

Subcutaneous nivolumab under review in EU for solid tumors

Hannah Clarke
The European Commission must issue a decision on the application on or by June 2, 2025.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
RAG-01 elicits complete responses in NMIBC
March 26th 2025

RAG-01 elicits complete responses in NMIBC

Hannah Clarke
"The striking CR rates observed in these early cohorts are highly encouraging, particularly for BCG-unresponsive NMIBC patients who currently have limited treatment options," says Paul D. Anderson, MBBS, FRACS.
Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC
March 26th 2025

Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC

Andrea Necchi, MD Hannah Clarke
"Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.
© 2025 MJH Life Sciences

All rights reserved.